SpyGlass Pharma, Inc. (SGP) — Working Capital to Net Assets Ratio
SpyGlass Pharma, Inc. (SGP) has a Working Capital to Net Assets ratio of 98.6% as of March 2026. Working capital of $246.69 Million (current assets of $253.36 Million minus current liabilities of $6.67 Million) is measured against net assets of $250.11 Million. A higher ratio indicates strong short-term liquidity financed by the equity base. See how financially flexible is SpyGlass Pharma, Inc. to measure the company's free cash flow as a share of total liabilities.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
SpyGlass Pharma, Inc. Working Capital to Net Assets (2023–2025)
This chart shows how SpyGlass Pharma, Inc.'s Working Capital to Net Assets ratio has evolved across 3 annual periods from 2023 to 2025. As of March 2026, the ratio stands at 98.6%, reflecting working capital of $246.69 Million against net assets of $250.11 Million USD. See how many days can SpyGlass Pharma, Inc. fund operations to measure how many days the company can operate on defensive assets alone.
Annual Working Capital to Net Assets for SpyGlass Pharma, Inc. (2023–2025)
The table below presents the year-by-year Working Capital to Net Assets ratio for SpyGlass Pharma, Inc. from 2023 to 2025, covering 3 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For live market cap and the full company profile, see SpyGlass Pharma, Inc. market capitalisation.
| Year | WC/NA Ratio | Working Capital (USD) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | -101.4% | $100.18 Million | $-98.84 Million | $108.77 Million | $8.58 Million | ▼ -85.5 pp |
| 2024 | -15.9% | $9.62 Million | $-60.47 Million | $17.41 Million | $7.79 Million | ▲ +102.4 pp |
| 2023 | -118.3% | $39.03 Million | $-32.99 Million | $40.61 Million | $1.59 Million | — |